| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | XCR2BZ80N7 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| DISRUPTING AGENT | DNA disrupting agent |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Breast Neoplasms | 3 | D001943 | ClinicalTrials |
| Breast Neoplasms | 3 | D001943 | ClinicalTrials |
| Hemangiosarcoma | 2 | D006394 | ClinicalTrials |
| Endometrial Neoplasms | 2 | D016889 | ClinicalTrials |
| Endometrial Neoplasms | 2 | D016889 | ClinicalTrials |
| Urinary Bladder Neoplasms | 1 | D001749 | ClinicalTrials |
| Stomach Neoplasms | 1 | D013274 | ClinicalTrials |
| Ovarian Neoplasms | 1 | D010051 | ClinicalTrials |
| Carcinoid Tumor | 1 | D002276 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL4298178 |
| FDA SRS | XCR2BZ80N7 |
CONTENTS